Estimation of the wound healing efficiency of the immunomodulator RV-2 in white mice

Abstract

The literature data on the use of immunomodulators of synthetic origin from the group of thymomimetics are present in this article. It is noted that peptide bioregulators have found wide application in surgical practice in human medicine while information on their use in veterinary medicine is limited to particular reports. It is showed that although the presented data indicate positive results of their application they do not give a sufficiently complete answer to the question of treatment tactics in regard to the beginning of bioregulatory therapy. In the experiment on white mice using an aseptic cutaneous-muscular wound model, the diversified wound healing effect of the immunomodulator RV-2 was demonstrated in correlation to the method of application of the drug, the severity of the lesion, the size of the wound defect and the onset of bioregulatory therapy. It is shown that for slight injuries taking into account the diminution of the area and wound healing rate it is preferable to localize the immunomodulator 24 hours after the wounding while intramuscular injection 24 to 120 hours after was inferior to the control group on these indicators. With more extensive wounds (an area 4.5-4.8 times larger), it is effective to perform preoperative drug treatment intramuscularly daily for five days, which reduces the duration of recovery compared to the control group by 1.9 days - from 18.7 ± 0,80 to 16.8 ± 0.80 days with a higher wound healing effect during the first 10 days. Use of the immunomodulator RV-2 120 hours after modeling of the wound has similar mechanism of ac tion. Local treatment of wound defect is ineffective.